Mineralys therapeutics announces late-breaking data from advance-htn pivotal trial of lorundrostat in uncontrolled and resistant hypertension presented at the american college of cardiology's annual scientific session & expo (acc.25)

– lorundrostat 50 mg dose achieved a 15.4 mmhg absolute reduction and 7.9 mmhg placebo-adjusted reduction (p=0.001), assessed by 24hr abpm at week 12, with favorable safety and tolerability profile –

ACC Ratings Summary

ACC Quant Ranking